Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE).
Year: 2012
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Matthew Raymond Smith, Christopher Sweeney, Dana E. Rathkopf, Howard I. Scher, Christopher Logothetis, Daniel J. George, Celestia S. Higano, Evan Y. Yu, Andrea Lynne Harzstark, Eric Jay Small, A. Oliver Sartor, Michael S. Gordon, Nicholas J. Vogelzang, David C. Smith, Maha Hussain, Johann Sebastian De Bono, Naomi B. Haas, Christian Scheffold, Yihua Lee, Paul G. Corn
Institutions: Massachusetts General Hospital, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Sidney Kimmel Center for Prostate and Urologic Cancers, The University of Texas MD Anderson Cancer Center, Duke Medical Center, Fred Hutch Cancer Center, University of California, San Francisco, Tulane University, Pinnacle Oncology Hematology, Comprehensive Cancer Centers of Nevada, University of Michigan, U-M Rogel Cancer Center, Institute of Cancer Research, Royal Marsden Hospital, Abramson Cancer Center, University of Pennsylvania, Exelixis (United States)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2612895014